Harvest Portfolios Group Inc. Acquires 54,371 Shares of Boston Scientific Co. (NYSE:BSX)

Harvest Portfolios Group Inc. increased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 7.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 750,216 shares of the medical equipment provider's stock after acquiring an additional 54,371 shares during the period. Boston Scientific makes up about 2.1% of Harvest Portfolios Group Inc.'s investment portfolio, making the stock its 6th biggest position. Harvest Portfolios Group Inc. owned approximately 0.05% of Boston Scientific worth $62,868,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BSX. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $26,000. Values First Advisors Inc. acquired a new stake in Boston Scientific during the 3rd quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. purchased a new position in Boston Scientific during the third quarter worth $30,000. First Foundation Advisors acquired a new position in shares of Boston Scientific in the first quarter worth $25,000. Finally, Eagle Bay Advisors LLC raised its holdings in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 309 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday. Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. upped their price objective on shares of Boston Scientific from $82.00 to $85.00 and gave the company an "overweight" rating in a research note on Thursday, July 25th. Royal Bank of Canada raised their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Finally, Citigroup boosted their price target on Boston Scientific from $92.00 to $98.00 and gave the company a "buy" rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and an average target price of $93.39.

Boston Scientific Stock Up 1.0 %

Shares of NYSE:BSX traded up $0.88 during mid-day trading on Wednesday, hitting $86.42. 6,203,806 shares of the company traded hands, compared to its average volume of 6,101,743. The firm has a market cap of $127.26 billion, a P/E ratio of 70.69, a PEG ratio of 2.46 and a beta of 0.79. Boston Scientific Co. has a 52-week low of $50.84 and a 52-week high of $88.79. The firm's 50 day simple moving average is $84.21 and its 200 day simple moving average is $78.68. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. The business's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 earnings per share. On average, equities analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now owns 34,748 shares in the company, valued at approximately $2,913,967.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the sale, the executive vice president now directly owns 34,748 shares of the company's stock, valued at approximately $2,913,967.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 309,270 shares of company stock valued at $26,196,718 in the last ninety days. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.